9EHL image
Deposition Date 2024-11-23
Release Date 2025-05-21
Last Version Date 2025-05-28
Entry Detail
PDB ID:
9EHL
Title:
Structure of HIV-1 BG505 SOSIP.664 Env trimer in complex with IOMAmin5 and 10-1074 Broadly Neutralizing Antibodies - Class I
Biological Source:
Source Organism:
Host Organism:
Method Details:
Experimental Method:
Resolution:
3.90 Å
Aggregation State:
PARTICLE
Reconstruction Method:
SINGLE PARTICLE
Macromolecular Entities
Structures with similar UniProt ID
Protein Blast
Polymer Type:polypeptide(L)
Molecule:HIV-1 BG505 SOSIP gp120,Envelope glycoprotein gp120
Gene (Uniprot):env
Mutagens:T326N,A494C
Chain IDs:A, B, C
Chain Length:506
Number of Molecules:3
Biological Source:Human immunodeficiency virus 1
Structures with similar UniProt ID
Protein Blast
Polymer Type:polypeptide(L)
Molecule:HIV-1 BG505 SOSIP gp41
Gene (Uniprot):env
Chain IDs:D, E, F
Chain Length:153
Number of Molecules:3
Biological Source:Human immunodeficiency virus 1
Polymer Type:polypeptide(L)
Molecule:IOMAmin5 Fab Heavy Chain
Chain IDs:G, H, I
Chain Length:128
Number of Molecules:3
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Molecule:IOMAmin5 Fab Light Chain
Chain IDs:J, K, L
Chain Length:111
Number of Molecules:3
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Molecule:10-1074 Fab Heavy Chain
Chain IDs:M, N, O
Chain Length:134
Number of Molecules:3
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Molecule:10-1074 Fab Light Chain
Chain IDs:P, Q, R
Chain Length:110
Number of Molecules:3
Biological Source:Homo sapiens
Ligand Molecules
Primary Citation
Mapping essential somatic hypermutations in a CD4-binding site bNAb informs HIV-1 vaccine design.
Cell Rep 44 115713 115713 (2025)
PMID: 40378041 DOI: 10.1016/j.celrep.2025.115713

Abstact

HIV-1 broadly neutralizing antibodies (bNAbs) targeting the CD4-binding site (CD4bs) contain rare features that pose challenges to elicit these bNAbs through vaccination. The IOMA class of CD4bs bNAbs includes fewer rare features and somatic hypermutations (SHMs) to achieve broad neutralization, thus presenting a potentially accessible pathway for vaccine-induced bNAb development. Here, we created a library of IOMA variants in which each SHM was individually reverted to the inferred germline counterpart to investigate the roles of SHMs in conferring IOMA's neutralization potency and breadth. Impacts on neutralization for each variant were evaluated, and this information was used to design minimally mutated IOMA-class variants (IOMAmin) that incorporated the fewest SHMs required for achieving IOMA's neutralization breadth. A cryoelectron microscopy (cryo-EM) structure of an IOMAmin variant bound to Env was used to further interpret characteristics of IOMA variants to elucidate how IOMA's structural features correlate with its neutralization mechanism, informing the design of IOMA-targeting immunogens.

Legend

Protein

Chemical

Disease

Primary Citation of related structures